You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

Dr. Elmariah, Professor Metz, and Dr. Kim discuss the unique clinical presentations of PN and CSU and explore the shared and distinct pathophysiological underpinnings of itch and inflammation in both diseases, with a focus on the roles of type 2 cytokines at the neuroimmune axis In PN and CSU

Sarina Elmariah
Martin Metz
Brian Kim
MD, PhD
Sarina Elmariah +2 more

Learning objectives

  • Comprehend the unique and significant burdens associated with chronic itch and skin lesions in PN and CSU
  • Understand the diverse actions of type 2 cytokines at the neuroimmune axis and how they perpetuate chronic itch and inflammation in PN and CSU
Tags
symposium
MAT-US-2403617 v1.0 - P Exp Date: 04/03/2026

About these experts

Dermatology
MD, PhD

Sarina Elmariah

Associate Professor and Dermatology Director at the UCSF Centre for Itch and Neurosensory Disorders at the University of California in San Francisco, California, US

Allergy/Immunology
MD

Martin Metz

Professor in the Department of Dermatology and Allergy, Head of Translational Research, and Deputy Head of Clinical Trials | Charité – Universitätsmedizin, Berlin, Germany

Dermatology
MD

Brian Kim

Professor, Vice Chair of Research, and Site Chair of Mount Sinai West, Icahn School of Medicine, NY, US

Related resources

Barrier Disruption in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Barrier Disruption in Atopic Dermatitis and Food Allergy

Type 2 Inflammation in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Type 2 Inflammation in Atopic Dermatitis and Food Allergy

Assessment of Atopic Dermatitis Burden in Children and Adolescents
Dermatology
expert video

Assessment of Atopic Dermatitis Burden in Children and Adolescents

Comorbidities in Children and Adolescents with Atopic Dermatitis
Dermatology
expert video

Comorbidities in Children and Adolescents with Atopic Dermatitis

Atopic Dermatitis as a Risk Factor for Food Allergy
Type 2 Inflammation
expert video

Atopic Dermatitis as a Risk Factor for Food Allergy

What is the disease burden of atopic dermatitis on children and their families
Dermatology
expert video

What is the disease burden of atopic dermatitis on children and their families

The Burden of Disease in Atopic Dermatitis
Dermatology
expert video

The Burden of Disease in Atopic Dermatitis

The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis
Dermatology
videoanimation

The Burden of Chronic Spontaneous Urticaria: One Patient’s Journey to Diagnosis

Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.
Dermatology
Infographic

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology
Dermatology
expert video

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

Disease Modification Concepts in AD
Dermatology
expert video

Disease Modification Concepts in AD

Barrier disruption in AD and the development of environmental and food allergies
Dermatology
expert video

Barrier disruption in AD and the development of environmental and food allergies

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

CSU is Associated With a High Burden and Impact on Quality of Life
Dermatology
expert video

CSU is Associated With a High Burden and Impact on Quality of Life

How type 2 cytokines can amplify inflammatory response in CSU
Dermatology
expert video

How type 2 cytokines can amplify inflammatory response in CSU

Type 2 Inflammation and Infections
Type 2 Inflammation
slide presentation

Type 2 Inflammation and Infections

Bullous Pemphigoid Mechanism of Disease Video
Dermatology
videoanimation

Bullous Pemphigoid Mechanism of Disease Video

Diagnosis of Bullous Pemphigoid Interactive Patient Case
Dermatology
interactivity

Diagnosis of Bullous Pemphigoid Interactive Patient Case

Differential Diagnosis and Disease Onset in Older Adult Patients With AD
Dermatology
expert video

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD
Dermatology
expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults
Dermatology
expert video

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

Is Pediatric AD Linked to Other Allergic Diseases?
Dermatology
expert video

Is Pediatric AD Linked to Other Allergic Diseases?

Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
expert video

Long-term Impacts of AD and the Potential Benefit of Early Intervention

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention
Dermatology
expert video

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

Practical Considerations in Older Patients with AD
Dermatology
expert video

Practical Considerations in Older Patients with AD

The Benefits of Early Intervention in AD: More Than Skin Deep
Dermatology
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion
Dermatology
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region